Bimekizumab-bkzx (Bimzelx).

The FDA has approved bimekizumab-bkzx for the management of moderate to severe plaque psoriasis in adults who are eligible for systemic therapy or phototherapy. Bimekizumab is a humanized monoclonal antibody that neutralizes key cytokines involved in inflammation. In a clinical trial, patients treated with bimekizumab achieved significant skin clearance within 16 weeks. The most common side effects include upper respiratory infections, oral candidiasis, headache, injection site reactions, and various infections. For more information, visit ucb.com. [Extracted from the article]

Copyright of Pharmacy Times is the property of MJH Life Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)